"Results of the largest Phase III study of acromegaly patients show the novel therapy pasireotide long-acting release, was significantly more effective at inducing full biochemical control compared to the current standard medical therapy," the company said in a statement.
(Reporting by Catherine Bosley)
Copyright 2013 mojeNovosti.com
web developer: BTGcms